$1.78
Insights on Xeris Biopharma Holdings Inc
Revenue is down for the last 2 quarters, 48.32M → 44.39M (in $), with an average decrease of 8.1% per quarter
Netprofit is down for the last 2 quarters, -12.18M → -13.39M (in $), with an average decrease of 9.9% per quarter
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 68.0%
0.28%
Downside
Day's Volatility :6.08%
Upside
5.82%
17.98%
Downside
52 Weeks Volatility :55.21%
Upside
45.4%
Period | Xeris Biopharma Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -26.75% | -0.4% | 0.0% |
6 Months | 5.33% | 9.6% | 0.0% |
1 Year | -22.27% | 3.9% | -1.3% |
3 Years | -2.2% | 12.8% | -22.1% |
Market Capitalization | 244.4M |
Book Value | - $0.05 |
Earnings Per Share (EPS) | -0.45 |
Wall Street Target Price | 4.75 |
Profit Margin | -37.98% |
Operating Margin TTM | -22.17% |
Return On Assets TTM | -8.25% |
Return On Equity TTM | -324.2% |
Revenue TTM | 163.9M |
Revenue Per Share TTM | 1.19 |
Quarterly Revenue Growth YOY | 33.900000000000006% |
Gross Profit TTM | 87.6M |
EBITDA | -31.7M |
Diluted Eps TTM | -0.45 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.38 |
EPS Estimate Next Year | -0.22 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.09 |
What analysts predicted
Upside of 166.85%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.5M | ↑ 58.42% |
Net Income | -60.1M | ↑ 126.26% |
Net Profit Margin | -2.4K% | ↓ 730.76% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.7M | ↑ 10.43% |
Net Income | -125.6M | ↑ 109.02% |
Net Profit Margin | -4.6K% | ↓ 2176.2% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 20.2M | ↑ 640.45% |
Net Income | -91.1M | ↓ 27.42% |
Net Profit Margin | -452.2% | ↑ 4161.32% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 49.6M | ↑ 146.04% |
Net Income | -122.7M | ↑ 34.66% |
Net Profit Margin | -247.48% | ↑ 204.72% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 110.2M | ↑ 122.32% |
Net Income | -94.7M | ↓ 22.87% |
Net Profit Margin | -85.86% | ↑ 161.62% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 163.9M | ↑ 48.68% |
Net Income | -62.3M | ↓ 34.23% |
Net Profit Margin | -37.98% | ↑ 47.88% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 33.2M | ↑ 31.18% |
Net Income | -26.6M | ↑ 1.61% |
Net Profit Margin | -80.15% | ↑ 23.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 38.0M | ↑ 14.5% |
Net Income | -19.8M | ↓ 25.43% |
Net Profit Margin | -52.2% | ↑ 27.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.2M | ↓ 12.66% |
Net Income | -16.8M | ↓ 15.16% |
Net Profit Margin | -50.71% | ↑ 1.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 38.0M | ↑ 14.5% |
Net Income | -19.8M | ↑ 17.87% |
Net Profit Margin | -52.2% | ↓ 1.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 48.3M | ↑ 27.13% |
Net Income | -12.2M | ↓ 38.57% |
Net Profit Margin | -25.23% | ↑ 26.97% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 44.4M | ↓ 8.13% |
Net Income | -13.4M | ↑ 9.85% |
Net Profit Margin | -30.16% | ↓ 4.93% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 120.0M | ↑ 166.74% |
Total Liabilities | 44.6M | ↓ 56.61% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 109.0M | ↓ 9.2% |
Total Liabilities | 94.6M | ↑ 111.89% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 159.2M | ↑ 46.03% |
Total Liabilities | 125.4M | ↑ 32.62% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 304.4M | ↑ 91.24% |
Total Liabilities | 209.1M | ↑ 66.78% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 344.5M | ↑ 13.2% |
Total Liabilities | 299.3M | ↑ 43.13% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 322.6M | ↓ 6.36% |
Total Liabilities | 329.4M | ↑ 10.04% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 321.4M | ↑ 0.86% |
Total Liabilities | 291.3M | ↑ 19.06% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 328.8M | ↑ 2.31% |
Total Liabilities | 315.1M | ↑ 8.18% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 321.4M | ↓ 2.26% |
Total Liabilities | 291.3M | ↓ 7.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 328.8M | ↑ 2.31% |
Total Liabilities | 315.1M | ↑ 8.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 327.8M | ↓ 0.3% |
Total Liabilities | 323.9M | ↑ 2.79% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 340.8M | ↑ 3.97% |
Total Liabilities | 347.6M | ↑ 7.3% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -56.3M | ↑ 128.19% |
Investing Cash Flow | -68.3M | ↑ 9651.57% |
Financing Cash Flow | 128.2M | ↑ 264.87% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -104.3M | ↑ 85.41% |
Investing Cash Flow | -2.4M | ↓ 96.51% |
Financing Cash Flow | 80.5M | ↓ 37.19% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -80.6M | ↓ 22.8% |
Investing Cash Flow | -27.4M | ↑ 1050.02% |
Financing Cash Flow | 126.1M | ↑ 56.54% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -95.5M | ↑ 18.59% |
Investing Cash Flow | 98.0M | ↓ 457.47% |
Financing Cash Flow | 27.2M | ↓ 78.39% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -102.9M | ↑ 7.7% |
Investing Cash Flow | 34.5M | ↓ 64.82% |
Financing Cash Flow | 127.5M | ↑ 367.84% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -26.1M | ↑ 26.84% |
Investing Cash Flow | 6.7M | ↓ 43.47% |
Financing Cash Flow | -863.0K | ↓ 378.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.7M | ↓ 47.42% |
Investing Cash Flow | 9.2M | ↑ 36.65% |
Financing Cash Flow | 556.0K | ↓ 164.43% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -26.1M | ↑ 90.19% |
Investing Cash Flow | 8.5M | ↓ 7.81% |
Financing Cash Flow | -863.0K | ↓ 255.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.7M | ↓ 47.42% |
Investing Cash Flow | 8.5M | ↑ 0.0% |
Financing Cash Flow | 556.0K | ↓ 164.43% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.6M | ↑ 6.3% |
Investing Cash Flow | 14.7M | ↑ 73.39% |
Financing Cash Flow | -72.0K | ↓ 112.95% |
Sell
Neutral
Buy
Xeris Biopharma Holdings Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Xeris Biopharma Holdings Inc | -15.64% | 5.33% | -22.27% | -2.2% | -2.2% |
Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Xeris Biopharma Holdings Inc | NA | NA | NA | -0.38 | -3.24 | -0.08 | NA | -0.05 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Xeris Biopharma Holdings Inc | Buy | $244.4M | -2.2% | NA | -37.98% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
BlackRock Inc
Vanguard Group Inc
Stonepine Capital Management Llc
Caxton Corp
MPM Oncology Impact Management LP
Rosalind Advisors, Inc.
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
Organization | Xeris Biopharma Holdings Inc |
Employees | 377 |
CEO | Mr. Paul R. Edick |
Industry | Health Technology |